Made in India new generation heart stent receives major global recognition

An Indian-made heart stent, Supraflex Cruz, has demonstrated a lower failure rate in high-risk patients compared to a US-made market leader. The TUXEDO-2 trial, conducted in India, showed the Indian stent to be non-inferior and resulted in significantly lower Target Lesion Failures, including cardiac death and heart attacks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aiTWQR7
via IFTTT

Read More

Cipla plans 4 major respiratory launches by 2026 after beating Q2 estimates with highest-ever quarterly revenue of Rs 7,500+ cr

Cipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growing chronic portfolio. The company maintained its second position in India's chronic market and saw significant progress in its U.S. respiratory and biosimilar segments, with four major respiratory assets slated for launch by 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vJO7TED
via IFTTT

Read More

Zero GST on health insurance plans sparks 38% surge in demand: Report

Health insurance demand has surged by 38 percent following the removal of GST. Individuals are now opting for higher coverage amounts, with the average sum insured increasing significantly. This trend is observed across various age groups and even in smaller cities. The exemption makes health and life insurance more affordable, encouraging comprehensive protection against rising healthcare costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PJdcy73
via IFTTT

Read More

Drug cos forging data for approval, mislabelling brands to be barred

In a bold move to combat deception in the pharmaceutical industry, the government is instituting strict penalties for drugmakers caught submitting forged or misleading documents during the approval process. This initiative is a direct response to the tragic incidents of child fatalities linked to tainted cough syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4ltOwLk
via IFTTT

Read More

Govt aligns packaging rules for medical devices, eases compliance burden

Attention healthcare providers: New packaging regulations for medical devices have just come into effect! These amendments are designed to ensure that packaging aligns seamlessly with existing medical device standards. This simplification not only supports businesses by streamlining compliance but also enhances clarity for consumers making informed choices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Yko71jI
via IFTTT

Read More

Amway to invest $12 million in India to enhance physical presence

Amway plans a USD 12 million investment in India over the next three to five years. This will establish new stores nationwide, aiming to boost Amway's presence. The company also intends to increase exports from India. Amway sees India as a significant growth market with strong potential for its health and wellness products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TCHlwZn
via IFTTT

Read More

Indian pharma & healthcare sector saw $3.5 bn deals in Q3 2025: Grant Thornton Bharat

The Indian pharmaceutical and healthcare sector saw robust deal activity in Q3, with 72 transactions totaling USD 3.5 billion. This surge, driven by a sharp rebound in private deals and high-value acquisitions like Torrent Pharma's stake in JB Chemicals, reflects renewed investor confidence in the sector's growth potential and consolidation plays.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZAxQeoK
via IFTTT

Read More

Sanofi India appoints Deepak Arora as Managing Director

Sanofi India has appointed Deepak Arora as its new Managing Director. Arora will lead the company's strategic vision for India, aligning it with Sanofi's global strategy. He will focus on accelerating innovation and agility across the organization. Arora brings over 30 years of pharmaceutical and healthcare experience from various international markets. His appointment aims to enhance patient service throughout India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pb75vEl
via IFTTT

Read More

Dr Reddy’s gets nod to make generic semaglutide for weight loss

Dr Reddy's Laboratories is set to launch generic semaglutide, a popular weight loss drug. An expert committee has approved their proposal. The company plans to market the drug as soon as Novo Nordisk's patent expires early next year. This move aims to tap into a growing market for obesity and diabetes management. Dr Reddy's is preparing for a competitive launch.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E4PLRBv
via IFTTT

Read More

Lupin launches generic drug to treat urea cycle disorders in US

Drug firm Lupin has launched a generic medication in the US. This new drug treats urea cycle disorders. It is an authorized generic version of Ravicti oral liquid. The medication helps patients manage the disorder. This is for those who cannot be managed by diet alone. Lupin's shares saw a slight dip on the BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/StLxhry
via IFTTT

Read More

Time has never been better for Pharma breakthroughs than today: Bayer executive Stefan Oelrich

Bayer, the renowned pharmaceutical powerhouse from Germany, is implementing a tiered pricing strategy on a global scale to make medications more accessible. The CEO emphasizes the necessity of earning returns to justify research investments. As innovation ecosystems shift, particularly towards regions like China, Bayer is proactively adapting.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/foMhiNY
via IFTTT

Read More

Eli Lilly allows Cipla to sell weight loss drug under new brand in India

Eli Lilly and Cipla have joined forces. Cipla will now market Lilly's popular weight-loss drug in India. The medication will be sold under the brand name Yurpeak. This drug helps manage diabetes and obesity. It is administered as a once-weekly injection. Yurpeak will be available in multiple dose strengths.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IX3GM0D
via IFTTT

Read More

Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IV

Biocon Biologics has made strides in the healthcare sector by obtaining Health Canada’s approval for Yesintek and Yesintek IV, its latest autoimmune treatment options. These biosimilars to Stelara have received official clearance on October 17, heralding a new era of affordable treatment in Canada.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/z9nY6Mk
via IFTTT

Read More

Trump eyes fresh tariff probe focused on foreign drug prices

President Trump is initiating a new investigation into drug prices, aiming to compel foreign nations to pay the same as Americans for their medicines. This probe, under Section 301 of the Trade Act, could lead to tariffs or other trade actions against countries with lower drug costs, potentially escalating global trade tensions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/diflSr2
via IFTTT

Read More

Regulator to digitally monitor supply chain of cough syrups

In a groundbreaking effort to enhance public health safety, India's drug regulatory authority has unveiled a digital tracking system for cough syrup supplies. This initiative comes in response to alarming cases of harmful cough syrups surfacing in the market. The revamped Online National Drugs Licensing System now requires pharmaceutical manufacturers of solvents to register and obtain licenses through this portal.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gkDGzXA
via IFTTT

Read More

COVID-19 vaccines may help some cancer patients fight tumors

New research suggests COVID-19 mRNA vaccines could help cancer patients. Those with advanced lung or skin cancer who received Pfizer or Moderna shots lived longer while on immunotherapy. The mRNA technology appears to enhance the immune system's ability to fight tumors. This finding offers a potential new approach for cancer treatment, with further studies planned.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1ZvlNyb
via IFTTT

Read More

CCI clears Torrent Pharma's proposal to buy stake in JB Chemicals

India's competition regulator CCI has approved Torrent Pharmaceuticals' acquisition of a stake in JB Chemicals and Pharmaceuticals. This deal, valued at Rs 19,500 crore, will make Torrent Pharmaceuticals the second most valued pharma company in India. The approval comes with voluntary modifications offered by both companies. This significant development marks a major consolidation in the Indian pharmaceutical sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pE0Q7tI
via IFTTT

Read More

Dr Reddy's Srikakulam unit classified as voluntary action indicated by USFDA

Dr Reddy's Laboratories has received a report from the US Food and Drug Administration. The report concerns its manufacturing facility in Srikakulam, Andhra Pradesh. The USFDA has classified the inspection outcome as Voluntary Action Indicated. This means the inspection is officially closed. The company received the Establishment Inspection Report on October 20, 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BPErcRQ
via IFTTT

Read More

Glenmark, Dr Reddy's recall products in US: USFDA

Indian drugmakers Glenmark and Dr Reddy's Laboratories are recalling products in the United States. Glenmark is recalling oral contraceptive medication due to failed impurities. Dr Reddy's Laboratories is recalling muscle relaxant medication due to out-of-specification results. These recalls are initiated by the US Food and Drug Administration. India has many USFDA-compliant plants outside the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BU49wPp
via IFTTT

Read More

India develops first indigenously discovered antibiotic "Nafithromycin" effective against resistant respiratory infections

India has proudly introduced Nafithromycin, its first homegrown antibiotic, tackling stubborn respiratory infections with groundbreaking efficacy. Coupled with a significant leap in gene therapy for Haemophilia, these innovations underscore India's commitment to self-sufficiency in the pharmaceutical arena. The country is now embracing a model that fosters collaboration with the private sector, setting the stage for international acclaim in biomedical research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sxOXMFd
via IFTTT

Read More

Strides Founder raises Rs 1000 crore to refinance debt

Arun Kumar, founder of Strides Group and OneSource, has secured ₹1,000 crore by pledging shares. This move refinances existing loans, extending maturities and simplifying repayments. The transaction aims to consolidate smaller borrowings into larger, long-term facilities. It reflects a broader effort to clean up the promoter's balance sheet and shows a decline in pledged shares, indicating deleveraging.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eUxw2VP
via IFTTT

Read More

Prerna launches CANTEL™: A MicroRNA-based blood test for breast cancer screening

PrecisionRNA Biotech from Hyderabad has launched Cantel, a new microRNA blood test for breast cancer screening. This test offers a simple and accurate alternative to traditional methods. It aims to improve early detection rates in India. Cantel is designed for women aged 30 and above. The company is seeking investors for nationwide expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FuEgW63
via IFTTT

Read More

Indian firms explore localisation of pharma production in Russia

The Russian market is attracting growing interest from Indian pharmaceutical companies exploring opportunities to establish production facilities across various regions of the country. This was announced by Moscow Government Minister and Head of the Department for External Economic and International Relations, Sergey Cheremin, during the " Russia-India. Mutual Efficiency" forum.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/amfci7u
via IFTTT

Read More

US Senator raises alarm over poor-quality drug imports from India and China, seeks tougher FDA inspections

In a letter to FDA Commissioner Martin Makary, Banks said the agency must "do more to protect the US drug supply," warning that lax oversight could endanger American consumers. He pointed out that inspections of foreign drug plants have not yet returned to pre-pandemic levels, even as the number of manufacturers continues to grow.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xEIYczF
via IFTTT

Read More

India to force drugmakers to upgrade plants after fatal cough syrup crisis

India has denied drugmakers more time to upgrade manufacturing facilities. This decision follows the deaths of at least 24 children from contaminated cough syrup. The government mandated World Health Organization standards after similar incidents abroad. Despite pleas from smaller firms, officials are firm on the deadline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jZH0vhU
via IFTTT

Read More

Alchem International moves Delhi HC against single-judge order on ‘Alchem’ trademark

Alchem International is challenging a court order that stops it from using its name. The order prevents Alchem from selling products with the name 'Alchem' due to similarity with Alkem Laboratories' trademark. A division bench is reviewing the case. The court previously found the names phonetically identical. Alkem has used its trademark since 1973. Alchem started using its mark later.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oKYmCbZ
via IFTTT

Read More

Heart blockages, tumors, fractures: Now, you can see what’s wrong inside your body in 3D at this Delhi govt hospital

Delhi-NCR's Vardhman Mahavir Medical College and Safdarjung Hospital has introduced a virtual clinical anatomy laboratory. Patients can now view detailed 3D models of their own bodies. This technology uses CT or MRI scans to create interactive visuals of organs, bones, and tissues. It helps patients understand their medical conditions and treatments better.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/imOeHXW
via IFTTT

Read More

Lords Mark Industries Ltd. secures US FDA Registration, reinforces India’s position in global healthcare manufacturing

Lords Mark Industries Ltd. has achieved a significant milestone with US FDA registration for its surgical consumables, orthopedic supports, and hygiene products. This recognition underscores the company's manufacturing excellence. It opens doors to international markets, boosting exports and India's global healthcare manufacturing standing. The approved portfolio covers a wide range of essential healthcare items.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3zsQDLj
via IFTTT

Read More

Under the scanner, yet generic cough syrups hit shelves

Worry spreads regarding the multitude of cough syrup brands circulating in India, with alarming revelations of toxic diethylene glycol detected in some, resulting in heartbreaking instances of child mortality. This situation sheds light on the questionable efficacy of regulatory measures, as many small-scale producers evade scrutiny.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kwLCu7p
via IFTTT

Read More

Centre plans new law for stricter quality checks and surveillance of drugs, medical devices, and cosmetics

India is creating a new law to improve drug quality and safety. This legislation will give more power to regulators for checking medicines, medical devices, and cosmetics. The aim is to prevent fake and substandard products. This move follows global concerns and recent incidents.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aYiSLR4
via IFTTT

Read More

Centre to bring law for strict quality checks, surveillance of drugs and cosmetics

India is creating a new law to improve drug quality and safety. This legislation will give more power to regulators for testing and monitoring medicines, medical devices, and cosmetics. The aim is to ensure stricter compliance and accountability. This move follows global concerns and recent incidents.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Fglp7bm
via IFTTT

Read More

Cloudnine Hospitals leads race to acquire Apollo Cradle

Cloudnine Hospitals is stepping into a pivotal role in the maternity and pediatric care sphere, as it engages in advanced discussions to acquire Apollo Cradle and Children's Hospital at a valuation of around ₹1,500 crore. Having signed an exclusivity pact, Cloudnine has kicked off due diligence procedures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NId1qZM
via IFTTT

Read More

Roche moves SC against Natco’s launch of generic Risdiplam in India

F. Hoffmann-La Roche AG has approached the Supreme Court. This follows a Delhi High Court decision permitting Natco Pharma to introduce a generic version of Risdiplam. Risdiplam treats spinal muscular atrophy. The High Court rejected Roche's plea to halt Natco's manufacturing. Natco plans to sell the drug at a significantly lower price.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7rRmOF1
via IFTTT

Read More

India accuses Balaji Amines of making pharma-grade chemical without a drug-making licence

Balaji Amines faces accusations from Indian authorities for producing pharma-grade propylene glycol without a necessary drug manufacturing license. This comes after some batches were found to be substandard. The company states it only manufactured technical and food-grade PG for non-pharma clients. Investigations are ongoing, and the company's stock has seen a decline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jFZ4eQd
via IFTTT

Read More

Aurobindo Pharma promoters raise Rs 2k cr to fund realty, other asset buys

The transaction is split into two parts. The Rs 650 crore Series 1 comes with a 24-month tenor and a two-year put and call option, and Rs 1,450 crore, which will be Series 2 with a four-year tenor. Series 1 will carry a coupon of 11.75%, while Series 2 is likely to be priced at 15.5%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9qK7MPH
via IFTTT

Read More

WHO warns of contaminated India cough syrups linked to 17 child deaths

The World Health Organization has issued a health advisory regarding three contaminated cough syrups from India. Specific batches of COLDRIF, Respifresh TR, and ReLife are identified. These products pose severe health risks. India's Central Drugs Standard Control Organization reported that 17 children under five died after consuming these syrups. Authorities confirm no contaminated medicines were exported from India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3HltM0L
via IFTTT

Read More

Cough Syrup deaths: Sresan Pharmaceuticals' license cancelled, company shut down

Tamil Nadu has cancelled the manufacturing license of Sresan Pharmaceutical, maker of Coldrif cough syrup, after it was linked to at least 22 deaths in Madhya Pradesh due to toxic contaminants. The state ordered comprehensive inspections of all pharmaceutical units following the incident and the arrest of the company owner.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PO1INFa
via IFTTT

Read More

ED raids seven Chennai sites linked to Sreesan Pharma over Coldrif cough syrup deaths

The Enforcement Directorate (ED) conducted searches at seven locations in Chennai concerning the Coldrif cough syrup case. These raids, under the PMLA, are linked to Sreesan Pharma, the manufacturer of the banned syrup. The cough syrup has been linked to the deaths of approximately 22 children, primarily in Madhya Pradesh and Rajasthan.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KQfagzI
via IFTTT

Read More

DRL, Zydus recall drugs in US over manufacturing issues: USFDA

Dr Reddy's Laboratories and Zydus Lifesciences are recalling products in the US due to manufacturing issues. Dr Reddy's is recalling muscle relaxant injections over stability testing failures, while Zydus Lifesciences is recalling antiviral medication for failing impurity specifications. Both recalls are classified as Class II by the USFDA.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u9rhU6i
via IFTTT

Read More

Survey finds 90% Indians willing to pay more for certified healthcare

A Ficci and EY-Parthenon report reveals that 83% of Indian patients desire accessible healthcare information, with nearly 90% willing to pay more for certified quality. Despite India's healthcare efficiency, a national framework for clear quality standards is needed to empower informed patient choices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SgXm82Z
via IFTTT

Read More

Breast cancer cases on rise; junk food, lack of exercise contributing factors: Doctors

Breast cancer is a growing concern in India, projected to reach two lakh cases annually by 2030. Experts highlight lifestyle factors like lack of exercise, obesity, and westernized diets as key contributors. Genetic predispositions also play a role, necessitating increased genetic testing and early screening for high-risk individuals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TrWEhVU
via IFTTT

Read More

Natco Pharma to acquire significant stake in S African firm Adcock Ingram

Indian pharmaceutical company Natco Pharma is set to acquire significant stakes in South Africa's Adcock Ingram, a 135-year-old firm, in a R4.2 billion deal. This acquisition will make Adcock Ingram a privately-held entity, co-owned by Natco and Bidvest, with Adcock Ingram delisting from the JSE post-completion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uCvon8O
via IFTTT

Read More

Max Healthcare plans over ₹5,000 crore expansion, eyes pan-India presence: MD Abhay Soi

Max Healthcare has surpassed ₹1 lakh crore in market capitalization, becoming India's most valued healthcare company. The company plans a significant capex of over ₹5,000 crore for expansion, aiming to increase bed capacity substantially and extend its reach into tier-2 and tier-3 cities across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8rt5jeA
via IFTTT

Read More

Panacea Biotec bags Rs 127 crore order for oral polio vaccines

Panacea Biotec has secured a significant deal to supply bivalent oral polio vaccines valued at Rs 127.2 crore to the Central Medical Services Society. This crucial supply, confirmed via a Letter of Acceptance, will be delivered in multiple phases over 90 to 480 days, bolstering India's ongoing polio eradication efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oU9hItu
via IFTTT

Read More

Trump & Co said to have shelved generic drug tariffs, Indian pharma stocks get booster dose

The Trump White House has halted plans for tariffs on generic drug imports, a decision welcomed by Indian pharmaceutical companies that supply nearly half of US generic prescriptions. This move reassures millions of Americans relying on affordable imported medications for various health conditions, averting potential price hikes and shortages.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ae6w8Wk
via IFTTT

Read More

MP cough syrup deaths: Maharashtra FDA orders inspection of liquid oral formulations

Following the deaths of 20 children in Madhya Pradesh due to a contaminated cough syrup, the Maharashtra FDA has initiated a special drive. This includes inspecting manufacturers and testing liquid oral formulations from hospitals and distributors to ensure quality and prevent similar incidents.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cJTtEmL
via IFTTT

Read More

Drug regulatory body steps up heat on state units amid cough syrup lapses

India's drug regulator has directed state authorities to enforce strict testing of all raw materials used in medicines. This action follows the tragic deaths of children due to contaminated cough syrups. Investigations revealed manufacturers were not testing excipients, leading to the use of industrial-grade materials unfit for human consumption.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mwY1vCO
via IFTTT

Read More

Eli Lilly's obesity drug Mounjaro's India sales hit a sweet spot within six months of launch

Lilly's Mounjaro has rapidly become the second-highest selling drug in India's pharmaceutical market, achieving ₹233 crore in sales within six months of its March launch. The weight-loss and diabetes medication posted ₹80 crore in September sales, surpassing popular brands and attributed to its superior efficacy and first-mover advantage over competitors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VGHjYOt
via IFTTT

Read More

Sresan Pharma, maker of Coldrif, broke multiple rules: Officials

Sresan Pharma, the manufacturer of Coldrif cough syrup linked to at least 16 child deaths, allegedly ignored numerous quality standards. A central inspection revealed a "shoddy and neglected state" at their Tamil Nadu facility, with significant violations in raw material testing and batch release.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tYyUbXI
via IFTTT

Read More

The first 90 days: A doctor’s checklist for people newly diagnosed with type 2 diabetes

The first 90 days after a type 2 diabetes diagnosis are crucial for managing the condition and reducing heart disease risks. Experts emphasize understanding the body's response to high blood sugar, adopting healthy lifestyle foundations like smart eating and regular exercise, and seeking support to lay the groundwork for long-term health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u2sLQ5r
via IFTTT

Read More

Eli Lilly to invest $1 billion in India, expand manufacturing and introduce oral weight-loss drug

Eli Lilly is significantly expanding its Indian operations with over $1 billion in contract manufacturing investments and plans for a global capability center. The US pharma giant is positioning India as a key hub, preparing to introduce an oral version of its experimental weight loss drug orforglipron and a new manufacturing hub in Hyderabad.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zgTGPxw
via IFTTT

Read More

"Classical example of legal illiteracy": IMA on arrest of doctor in child deaths from contaminated cough syrup

The Indian Medical Association has condemned the arrest of a pediatrician in Madhya Pradesh following child deaths from contaminated cough syrup, calling it "legal illiteracy" by police. The IMA demands action against actual culprits and compensation for affected families, emphasizing regulatory failures and the spurious nature of the drug.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kPIKN2R
via IFTTT

Read More

Kerala bars all medicines for children under 12 without prescription

Kerala's Health Department mandated doctor prescriptions for all medicines given to children under 12, citing cough syrup concerns. An expert panel will study cough medicine use to formulate new guidelines. This follows reports of child deaths outside Kerala linked to toxic cough syrups, prompting awareness campaigns and suspension of problematic batches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NrbwHzf
via IFTTT

Read More

Nanavati Max Hospital inks pact with Namangan Viloyat Republic Hospital in Uzbekistan

Mumbai's Nanavati Max Super Speciality Hospital has partnered with Uzbekistan's Namangan Viloyat Republic Hospital to enhance medical services. This collaboration facilitates knowledge exchange and clinician training in key specialties like multi-organ transplantation, while also providing advanced treatment for Uzbek patients in India. The agreement aims to establish transplant programs and streamline patient care pathways.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Hz69rVK
via IFTTT

Read More

Eli Lilly to invest over $1 billion in India to expand manufacturing capacity

Eli Lilly will invest over $1 billion in India to boost manufacturing and supply through local drugmakers, increasing the availability of key drugs like Mounjaro. This strategic move leverages India's skilled workforce and includes a new Hyderabad facility to oversee contract manufacturing, despite global shifts towards US production.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xzfFbtB
via IFTTT

Read More

Cough syrup issue: Health ministry directs rational use of medication

Union health secretary convened a meeting with states to address drug quality after multiple child deaths linked to contaminated cough syrups like Coldrif, found with DEG/EG. States were directed on rational use, while DGHS advised against prescribing such medicines for children under two, emphasizing careful evaluation for older kids. Probes are underway, and some states have banned the syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fpu3oe4
via IFTTT

Read More

NSE to build Rs 380-crore facility for cancer treatment at Tata Memorial Centre

NSE will build a 380 crore rupee cancer treatment facility at Tata Memorial Hospital. This 11-storey block and bone marrow transplant centre will be in Navi Mumbai. It will serve 1.3 lakh outpatients and conduct over 600 BMTs annually. The facility will have 60 beds. Operations are expected to begin by July 2027.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E3MQqC6
via IFTTT

Read More

India's TB fight gets a boost: New Made-in-India diagnostic tests cut cost & time

India's ICMR has validated two new indigenous TB diagnostic tools from Huwel Lifesciences. The Quantiplus MTB FAST kit offers cheaper, open-system RT-PCR testing on existing machines, while UniAMP MTB uses non-invasive tongue swabs for patient-friendly diagnosis. These innovations promise faster, more accessible, and affordable TB detection, boosting India's elimination efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HYprjS0
via IFTTT

Read More

Torrent Pharma gets demand notices totalling Rs 6.63 cr from NPPA

Torrent Pharmaceuticals reported receiving demand notices from the NPPA. The notices total over Rs 6.63 crore. They allege overcharging for five drugs between January 2016 and November 2018. The company stated these notices were received on October 3, 2025. Torrent Pharmaceuticals expects no material financial impact from this development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yrTJDqE
via IFTTT

Read More

Health Ministry confirms Diethylene Glycol beyond permissible limits in Coldrif cough syrup amid child deaths in Raj, MP

The Ministry of Health confirmed Coldrif Cough Syrup from Sresan Pharma's Kanchipuram unit contained diethylene glycol (DEG) above permissible limits, following investigations into child deaths in Madhya Pradesh and Rajasthan. Tamil Nadu banned its sale, halting production. Authorities initiated risk-based inspections and advised against prescribing cough syrup to children under two.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q1aO7u2
via IFTTT

Read More

Tamil Nadu bans ''Coldrif'' cough syrup after child deaths in MP, Rajasthan

Tamil Nadu has banned the sale of 'Coldrif' cough syrup, manufactured by a city-based firm, following suspicions linking it to 11 child deaths in Madhya Pradesh and Rajasthan. Inspections were conducted, and samples are being tested for Diethylene Glycol. The Union Health Ministry also advised against prescribing cough and cold medications for children under two years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y2LmXx6
via IFTTT

Read More

Isabgol processors threaten to halt purchases from October 6 over GST

Isabgol processors threaten to halt purchases from farmers due to GST ambiguities, locking up capital for over a year. The industry, exporting ₹3,500 crore annually, faces financial stress and slowed exports as unclear classifications force them to pay GST on seeds, despite refunds. They demand government clarification.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/szVjFdB
via IFTTT

Read More

Indian Pharmaceutical Alliance appoints Zydus Lifesciences MD Sharvil Patel as new president

The Indian Pharmaceutical Alliance (IPA) has appointed Sharvil Patel of Zydus Lifesciences as its new President, with Glenn Saldanha of Glenmark as Vice President. This leadership transition occurs as the industry navigates GST reforms and strengthens its global position in specialty medicines. The new team aims to drive innovation, patient access, and quality healthcare solutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/h4iGfDN
via IFTTT

Read More

IPA names Zydus Lifesciences MD Sharvil Patel as President

Sharvil Patel is the new president of the Indian Pharmaceutical Alliance. He takes over from Samir Mehta. Glenn Saldanha becomes the vice president. The IPA represents 23 national pharmaceutical companies. The new team will build on reforms and breakthroughs. They will focus on innovation, patient access, and quality in healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GYj4I3U
via IFTTT

Read More

Panacea Biotec gets supply order from UNICEF for oral polio vaccines worth Rs 315 cr

Panacea Biotec has received a long-term supply order from UNICEF. The order is for bivalent oral polio vaccines. It is valued at USD 35.65 million. Supplies will commence from April 2026 and continue until March 2030. This agreement covers vaccine requirements for UNICEF. The company will provide vaccines in 10 and 20 vial presentations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ra1qZi5
via IFTTT

Read More

Government invites proposals under PRIP scheme for industry, startup projects

The government has invited applications for its Rs 5,000 crore Pharma-MedTech innovation scheme, aiming to support around 300 projects in new medicines, biosimilars, and medical devices. Revised guidelines offer enhanced financial assistance for MSMEs and startups, including higher support for strategic priority areas. Applications opened on October 1 via a digital portal.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zx32rmn
via IFTTT

Read More

Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say

Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European Association for the Study of Obesity published in Nature Medicine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MtGbVzl
via IFTTT

Read More

Pricing depends on the country, Bayer looks at affordability: Executive

India has evolved significantly in the clinical trial setting...we have a significant number of patients and trials running in IndiaAshraf Al-Ouf Head, Pharmaceutical Commercial Ops, APAC, Bayer

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HNKCDW5
via IFTTT

Read More

'Contaminated' cough syrup linked deaths: NCDS collects water, entomological drug samples

NCDC collected water and entomological drug samples from Madhya Pradesh and Rajasthan after multiple children died of kidney failure, allegedly linked to contaminated cough syrup. These samples will be tested for infectious diseases, while state drug authorities await results from drug sample tests. Six children died in MP and one in Rajasthan, prompting a ban on 19 syrup batches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Pf9E8HG
via IFTTT

Read More

Indian pharma Wockhardt seeks US approval for new drug to treat UTIs

Wockhardt has submitted a New Drug Application to the USFDA for its novel antibacterial agent, Zidebactam-Cefepime injection. This drug targets complicated urinary tract infections, including those caused by multidrug-resistant Gram-negative bacteria. This marks a significant milestone as the first USFDA NDA for a drug fully discovered and developed by an Indian pharmaceutical company, following successful global Phase III trials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RVx0eK2
via IFTTT

Read More